Government Funding and Grants

Capital formation challenges in the industry have forced many biotech companies to halt projects, lay off staff or shutdown all together. Our analysis shows that the industry is approximately one-quarter smaller than it was in 2008.

BIO believes that the level of support provided by the TDP simply cannot meet the needs of the growing biotech field. As evidence of the project's popularity suggests, Congress should consider extending or expanding the project in order to support American innovation and speed the development of life-saving cures.

The biotech industry is a thriving sector employing 1.3 million Americans in high quality, high paying jobs.

Acorda Therapeutics' Ron Cohen presented testimony on the importance of federal policies to support the biotechnology industry at a House Committee on Science, Space and Technology, Subcommittee on Technology and Innovation hearing on March 27, a summary of his testimony is presented here

State governments in 2011 continued to see regional economic growth in the life sciences industry and in 2012 will increasingly focus attention on technology transfer and venture funding as mechanisms to increase private sector innovation related activities within their jurisdictions. Realizing that entrepreneurship is a key ingredient in economic development, states and localities are undertaking the support of programs that assist high technology businesses, and that capitalize on state regional presence of universities and federal laboratories.

Congress has the opportunity to help speed lifesaving cures and treatments to patients by removing burdens to innovation in our industry.

Jobs and salaries in this industry have substantially grown in the past ten years. To date, there are more than 47,000 bioscience companies and 1.4 million workers in the United States.

The Small Business Innovation Research Grants Program Provides Critical Support to Small Biotech Companies Working on Promising Innovations

Jack discusses her greatest accomplishments, advice for industry leaders, and the promise of biotech. Pulmatrix is a clinical trial stage biotech company based in Lexington, Mass.

On July 26, Agriculture Secretary Tom Vilsack announced four new project areas for the Biomass Crop Assistance Program.

What is your opinion of biotechnology companies – very favorable, somewhat favorable, somewhat unfavorable, or very unfavorable?

Society has tapped just a small fraction of the many potential uses and benefits of biotechnology.

BIO and five member companies – Mendel Biotechnology, Arborgen, Abengoa Bioenergy, Novozymes and BP Biofuels – along with the Biomass Power Association held a briefing on Capitol Hill this week, outlining the importance of the USDA’s Biomass Crop Assistance Program (BCAP) and related programs. Regulatory rules for the BCAP, Biorefinery Assistance Program, and Rural Energy for America Program (REAP) were finalized by USDA only during the last quarter of 2010. But Congress is considering cutting the funds for these programs before they have a chance to show their effectiveness.

"The Value Proposition for Cellulosic and Advanced Biofuels Under the Federal Renewable Fuel Standard" is forthcoming in the April 2011 Industrial Biotechnology Journal.

January 24 2013
To ensure transparency and communication between patients and their treatment teams, BIO believes that certain safeguards should guide substitution policies for interchangeable biologics under state law as well.
May 25 2011
Representatives of the bioscience industry testified before the U.S. Congress Joint Economic Committee today, as part of a hearing entitled Driving Innovation and Job Growth through the Life Sciences Industry.
April 1 2011
BIO submitted comments in response to the Request for Comments on the Strategy for American Innovation issued by the U.S. Department of Commerce. BIO addressed policies relating to government research and development, entrepreneurship, intellectual property, and incentives to innovate. BIO encouraged the Department of Commerce to help create an environment conducive to risk-taking and one that will unleash the tremendous potential of biotechnology.
January 11 2011
BIO and 23 other renewable energy groups have joined together in a letter to the White House requesting full funding and support of the Department of Agriculture's renewable energy program in the President's Budget for fiscal year 2012.
May 27 2010
The paper highlights factors that contribute to enabling environments for promising technologies to gain access to early capital.
April 16 2013
Bill would allow emerging biotech companies to maintain a working relationship with their independent auditor.
October 26 2011
 BIO Commends Governor Nixon and Missouri Legislature for Commitment to Industry
September 9 2011
BIO President and CEO Jim Greenwood released the following statement on President Obama’s speech to Congress last night on “The American Jobs Act.”
June 29 2011
“Unleashing the Promise of Biotechnology: Advancing American Innovation to Cure Disease and Save Lives” Provides Roadmap for Transformative Policy Changes
April 19 2011
The federal Renewable Fuel Standard provides the stable market support and pricing system necessary to attract private investment to the development of advanced biofuels.